false
Catalog
Treating Co-Occurring Opioid Use Disorder in Menta ...
handout: slides_s4210902-2
handout: slides_s4210902-2
Back to course
Pdf Summary
This document is a summary of a webinar titled "Treating Co-Occurring Opioid Use Disorder in Mental Health Settings." The webinar was part of the Clinical Support System for Serious Mental Illness (CSS-SMI) initiative funded by the Substance Abuse and Mental Health Services Administration (SAMHSA). The presenter of the webinar was Dr. Brian Hurley, the Medical Director of Substance Abuse Prevention and Control for the County of Los Angeles Department of Public Health.<br /><br />The webinar aimed to provide information on screening and diagnosing opioid use disorder (OUD), the three FDA-approved medications for OUD, and the integration of medication treatment into mental health programs. It emphasized the common occurrence of co-occurring substance use and mental health disorders, with approximately 29% of individuals with OUD having depression, 22% having anxiety, and 27% having bipolar disorder.<br /><br />The webinar highlighted the benefits of medication treatment for OUD, such as decreased mortality, increased treatment retention, and decreased illicit opioid use. It discussed the three medications commonly used for OUD: methadone, buprenorphine, and naltrexone. The presenter provided guidance on prescribing buprenorphine and starting naltrexone treatment, as well as the importance of psychosocial support in conjunction with medication treatment.<br /><br />The document also touched on topics such as the integration of substance use services into mental health settings, the use of quality metrics for COD treatment, and billing and treatment planning for co-occurring disorders.<br /><br />Overall, the webinar aimed to provide healthcare professionals with information and guidance on effectively treating individuals with co-occurring opioid use disorder and mental health disorders in mental health settings.
Keywords
Opioid Use Disorder
Mental Health Settings
Co-Occurring Disorders
Medication Treatment
Screening and Diagnosing
FDA-Approved Medications
Psychosocial Support
Integration of Services
Quality Metrics
Healthcare Professionals
Funding for SMI Adviser was made possible by Grant No. SM080818 from SAMHSA of the U.S. Department of Health and Human Services (HHS). The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, SAMHSA/HHS or the U.S. Government.
×
Please select your language
1
English